Remimazolam Tosilate for Injection
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastroscopic and Colonoscopic Sedation
Conditions
Gastroscopic and Colonoscopic Sedation
Trial Timeline
Jan 30, 2022 → Feb 8, 2023
NCT ID
NCT05254366About Remimazolam Tosilate for Injection
Remimazolam Tosilate for Injection is a pre-clinical stage product being developed by Jiangsu Hengrui Medicine for Gastroscopic and Colonoscopic Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT05254366. Target conditions include Gastroscopic and Colonoscopic Sedation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05549791 | Pre-clinical | Completed |
| NCT05254366 | Pre-clinical | Completed |